Kinase Inhibitors from Early Research to Clinic

24th June 2010
 AstraZeneca, Alderley Park Conference Centre, Alderley Park, Macclesfield

Protein kinases have become the second most exploited group of drug targets based on the critical role they play in cellular growth, apoptosis and signalling networks. To date, of the nine small molecule approved kinase inhibitors on the market, eight are targeted toward the treatment of oncology indications. Numerous kinases have also been validated as key components for therapeutic intervention in autoimmune, cardiovascular and inflammatory disorders, although the paucity of such inhibitors reaching the market may reflect the increased challenges in delivering safe and selective inhibitors.

This SMR symposium brings together a panel of international speakers across the breadth of research and development in the field of kinase drug discovery, to present and discuss new advances and results from early research to clinical data. Topics include kinase inhibitor design and translating kinase selectivity profiles into early safety guidance, and the discovery and early development of kinase inhibitors in the therapeutic areas of inflammation, pulmonary arterial hypertension, osteoarthritis (OA) induced pain and oncology.
 

• Download the programme and registration form
• View the programme online
• Map
• Directions
• Register Online